ArticleAsian journal of pharmaceutical sciences2017
Inclusion complex of tamibarotene with hydroxypropyl-β-cyclodextrin: Preparation, characterization,
Article in Asian journal of pharmaceutical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 25 citations in OpenAlex.
- Cyclodextrin-Based Inclusion Complexes Improve the In Vitro Solubility and Pharmacokinetics of Ivacaftor Following Oral Administration in Mice.AAPS PharmSciTech · 2025Article
- Article
- The Biological Fate of Pharmaceutical Excipient β-Cyclodextrin: Pharmacokinetics, Tissue Distribution, Excretion, and Metabolism of β-Cyclodextrin in Rats.Molecules (Basel, Switzerland) · 2022Article
- Increase in the Antioxidant and Anti-Inflammatory Activity ofInternational journal of molecular sciences · 2021Article
- A donepezil/cyclodextrin complexation orodispersible film: Effect of cyclodextrin on taste-masking based on dynamic process andAsian journal of pharmaceutical sciences · 2019Article
- Preparation and characterization ofAsian journal of pharmaceutical sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of this study was to improve the solubility and oral bioavailability of tamibarotene by complexing it with hydroxypropyl-β-cyclodextrin (HP-β-CD). The inclusion complex of tamibarotene with hydroxypropyl-β-cyclodextrin (Am80-HP-β-CD) was prepared through a freeze-drying method at the mole ratio of 1:1 (Am80: HP-β-CD). Fourier transform infrared spectroscopy (FT-IR) and differential scanning calorimetry (DSC) indicated the formation of Am80-HP-β-CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.